Q4 2025 · 13F-HR
Propel Bio Management, LLCholdings as filed
Filed 2026-02-11 · accession 0000898432-26-000087
$117.1M
Reported value
20
Positions
2025-12-31
Period end
The Brief · Propel Bio Management, LLC · Q4 2025
AI · grounded in 13F
Propel Bio Management, LLC closed its position in Akero Therapeutics Inc AKRO, reducing exposure by $10.87M. The fund established new positions in Kyverna Therapeutics Inc KYTX for $6.27M and Inventiva SA - ADR IVA for $4.65M. Additionally, the manager increased its stake in Viridian Therapeutics Inc VRDN by 213.92%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 72651A207 | PAGP | PLAINS GP HLDGS L P | $24.4M | 20.8% | 1,272,360 | Common | SHARED |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $18.8M | 16.1% | 3,786,425 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $12.3M | 10.5% | 740,918 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $8.8M | 7.51% | 282,531 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS | $8.3M | 7.10% | 4,118,321 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $6.3M | 5.35% | 666,666 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $5.9M | 5.08% | 861,778 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA - ADR | $4.7M | 3.97% | 1,000,000 | Common | SOLE |
| 24661P807 | DCTH | DELCATH SYSTEMS INC | $4.4M | 3.78% | 438,509 | Common | SHARED |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $4.4M | 3.74% | 830,780 | Common | SHARED |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC | $4.2M | 3.58% | 154,300 | Common | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $3.5M | 2.99% | 82,822 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $3.5M | 2.95% | 172,839 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $2.4M | 2.08% | 652,881 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $1.7M | 1.44% | 116,896 | Common | SOLE |
| 04746L203 | LONA | ATHIRA PHARMA INC | $1.1M | 0.96% | 149,279 | Common | SHARED |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $945,360 | 0.81% | 59,085 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $609,105 | 0.52% | 46,408 | Common | SOLE |
| 488445206 | ZVRA | ZEVRA THERAPEUTICS INC | $570,600 | 0.49% | 63,683 | Common | SHARED |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $354,927 | 0.30% | 42,053 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.